JP2015520187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520187A5 JP2015520187A5 JP2015516008A JP2015516008A JP2015520187A5 JP 2015520187 A5 JP2015520187 A5 JP 2015520187A5 JP 2015516008 A JP2015516008 A JP 2015516008A JP 2015516008 A JP2015516008 A JP 2015516008A JP 2015520187 A5 JP2015520187 A5 JP 2015520187A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- heterocyclic group
- compound
- formula
- fbxo3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026078 F-box only protein 3 Human genes 0.000 claims 12
- 101000913305 Homo sapiens F-box only protein 3 Proteins 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 235000019371 penicillin G benzathine Nutrition 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- -1 benzathine compound Chemical class 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical class C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102100037309 F-box/LRR-repeat protein 2 Human genes 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 101001026881 Homo sapiens F-box/LRR-repeat protein 2 Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 241001420836 Ophthalmitis Species 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000037903 inflammatory enteropathy Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical compound O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 208000010403 panophthalmitis Diseases 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000034512 ubiquitination Effects 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *c1c(*)c(*)nc(CN*NCc2nc(*)c(*)c(*)c2*)c1* Chemical compound *c1c(*)c(*)nc(CN*NCc2nc(*)c(*)c(*)c2*)c1* 0.000 description 1
- IXEPQJQQSLMESJ-UHFFFAOYSA-N C(CNCc(cc1)ccc1-c1ccccn1)NCc(cc1)ccc1-c1ccccn1 Chemical compound C(CNCc(cc1)ccc1-c1ccccn1)NCc(cc1)ccc1-c1ccccn1 IXEPQJQQSLMESJ-UHFFFAOYSA-N 0.000 description 1
- KQSIIKXPYURFEK-UHFFFAOYSA-N C(CNCc(cc1)ccc1-c1ncccn1)NCc(cc1)ccc1-c1ncccn1 Chemical compound C(CNCc(cc1)ccc1-c1ncccn1)NCc(cc1)ccc1-c1ncccn1 KQSIIKXPYURFEK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657423P | 2012-06-08 | 2012-06-08 | |
| US61/657,423 | 2012-06-08 | ||
| PCT/US2013/030995 WO2013184202A1 (en) | 2012-06-08 | 2013-03-13 | Fbxo3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520187A JP2015520187A (ja) | 2015-07-16 |
| JP2015520187A5 true JP2015520187A5 (enExample) | 2016-04-28 |
| JP6275703B2 JP6275703B2 (ja) | 2018-02-07 |
Family
ID=49712430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516008A Active JP6275703B2 (ja) | 2012-06-08 | 2013-03-13 | Ｆｂｘｏ３阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US9359284B2 (enExample) |
| EP (1) | EP2858975B1 (enExample) |
| JP (1) | JP6275703B2 (enExample) |
| KR (1) | KR102179006B1 (enExample) |
| CN (2) | CN104684895B (enExample) |
| AU (2) | AU2013272288B2 (enExample) |
| BR (1) | BR112014030720A8 (enExample) |
| CA (1) | CA2875305C (enExample) |
| ES (1) | ES2734567T3 (enExample) |
| IL (1) | IL235919A (enExample) |
| IN (1) | IN2014DN11078A (enExample) |
| MX (1) | MX369290B (enExample) |
| PL (1) | PL2858975T3 (enExample) |
| PT (1) | PT2858975T (enExample) |
| SG (1) | SG11201408171SA (enExample) |
| WO (1) | WO2013184202A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013272288B2 (en) * | 2012-06-08 | 2018-01-18 | The United States Government As Represented By The Department Of Veterans Affairs | FBXO3 inhibitors |
| US9849098B2 (en) | 2013-12-09 | 2017-12-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for treating respiratory injury or disease |
| CN107207407B (zh) * | 2014-12-10 | 2020-12-01 | 高等教育联邦系统-匹兹堡大学 | 用于治疗疾病和病症的组合物和方法 |
| EA034912B1 (ru) | 2015-06-03 | 2020-04-06 | Бристол-Маерс Сквибб Компани | 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний |
| JP6622822B2 (ja) * | 2015-06-23 | 2019-12-18 | ノビリス セラピューティクス インコーポレイテッド | 希ガス組成物を用いた治療的な免疫調節 |
| CA3045208A1 (en) | 2016-12-02 | 2018-06-07 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis |
| CN113663071B (zh) * | 2021-06-28 | 2022-12-30 | 四川大学 | Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途 |
| CN114805637B (zh) * | 2022-05-31 | 2023-02-03 | 中国科学院海洋研究所 | 一种海洋生物多糖席夫碱衍生物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2438288A1 (de) * | 1974-08-09 | 1976-02-19 | Knoll Ag | Neue antiarrhythmika |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US20030013772A1 (en) * | 2000-02-23 | 2003-01-16 | Murphy Michael A. | Composition, synthesis and therapeutic applications of polyamines |
| US6221914B1 (en) * | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| JP2000143665A (ja) * | 1998-11-10 | 2000-05-26 | Agency Of Ind Science & Technol | ゼオライトの製造方法 |
| JP2001127869A (ja) | 1999-10-25 | 2001-05-11 | Matsushita Electric Ind Co Ltd | 携帯電話装置の制御方法および携帯電話装置 |
| US6867299B2 (en) | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
| IL151692A0 (en) | 2000-03-24 | 2003-04-10 | Mediquest Therapeutics Inc | Polyamine analogues as cytotoxic agents |
| JP2001278869A (ja) | 2000-03-31 | 2001-10-10 | Chemiprokasei Kaisha Ltd | １，４−ビス（２ｈ−ベンゾトリアゾリル）ピペラジン誘導体、その製造法及び用途 |
| AU2003218729A1 (en) * | 2002-03-12 | 2003-09-22 | 4Sc Ag | Bis-aniline derivatives useful as potassium channels modulators |
| US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
| US7456222B2 (en) * | 2002-05-17 | 2008-11-25 | Sequella, Inc. | Anti tubercular drug: compositions and methods |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| EP2465855A1 (en) * | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
| WO2008142623A2 (en) * | 2007-05-17 | 2008-11-27 | Piramal Life Sciences Limited | Tumor necrosis factor - alpha inhibitors |
| AU2013272288B2 (en) * | 2012-06-08 | 2018-01-18 | The United States Government As Represented By The Department Of Veterans Affairs | FBXO3 inhibitors |
| US9849098B2 (en) * | 2013-12-09 | 2017-12-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for treating respiratory injury or disease |
| CN107207407B (zh) * | 2014-12-10 | 2020-12-01 | 高等教育联邦系统-匹兹堡大学 | 用于治疗疾病和病症的组合物和方法 |
-
2013
- 2013-03-13 AU AU2013272288A patent/AU2013272288B2/en active Active
- 2013-03-13 US US14/406,189 patent/US9359284B2/en active Active
- 2013-03-13 EP EP13800256.3A patent/EP2858975B1/en active Active
- 2013-03-13 CN CN201380042067.5A patent/CN104684895B/zh active Active
- 2013-03-13 IN IN11078DEN2014 patent/IN2014DN11078A/en unknown
- 2013-03-13 BR BR112014030720A patent/BR112014030720A8/pt active Search and Examination
- 2013-03-13 PL PL13800256T patent/PL2858975T3/pl unknown
- 2013-03-13 CN CN201710755434.6A patent/CN107569483B/zh active Active
- 2013-03-13 CA CA2875305A patent/CA2875305C/en active Active
- 2013-03-13 JP JP2015516008A patent/JP6275703B2/ja active Active
- 2013-03-13 WO PCT/US2013/030995 patent/WO2013184202A1/en not_active Ceased
- 2013-03-13 PT PT13800256T patent/PT2858975T/pt unknown
- 2013-03-13 MX MX2014015039A patent/MX369290B/es active IP Right Grant
- 2013-03-13 KR KR1020157000305A patent/KR102179006B1/ko active Active
- 2013-03-13 ES ES13800256T patent/ES2734567T3/es active Active
- 2013-03-13 SG SG11201408171SA patent/SG11201408171SA/en unknown
-
2014
- 2014-11-26 IL IL235919A patent/IL235919A/en active IP Right Grant
-
2016
- 2016-04-25 US US15/138,137 patent/US10159674B2/en active Active
- 2016-04-25 US US15/138,120 patent/US10307423B2/en active Active
-
2018
- 2018-04-11 AU AU2018202544A patent/AU2018202544B2/en active Active
- 2018-10-10 US US16/156,902 patent/US10369150B2/en active Active
-
2019
- 2019-06-18 US US16/444,879 patent/US10869866B2/en active Active
-
2020
- 2020-11-19 US US16/953,201 patent/US11857550B2/en active Active